Glucose‐lowering medicines use before and after entry into long‐term care facilities

Abstract

AimTo examine changes in the use of glucose‐lowering medicine (GLM) 12 months before and 12 months after long‐term care facility (LTCF) entry among people with diabetes.Materials and MethodsA national retrospective cohort study was conducted using linked health and aged care data from the Registry of Senior Australians National Historical Cohort. Residents of LTCFs with diabetes aged 65 years or older from 2015 to 2019 were included. Prevalence of GLM use and the number of defined daily doses (DDDs) dispensed per 1000 resident‐days were estimated quarterly (91‐day) using Poisson regression models, or negative binomial regression when overdispersion was present.ResultsAmong the 50 993 residents studied (median age 84 years), the prevalence of GLM use was 58.4% (95% confidence interval [CI] 58.0%‐58.8%) in the 9‐12 months pre‐LTCF entry and 56.3% (95% CI 55.9%‐56.8%) in the 9‐12 months post‐entry. The number of DDDs/1000 resident‐days increased from 1015.2 (95% CI 1002.3‐1028.1) to 1253.8 (95% CI 1168.4‐1339.3) during the same period. GLM use in the 3 months pre‐entry was 56.8% (95% CI 56.4%‐57.2%) compared with 61.7% (95% CI 61.3%‐62.1%) in the 3 months post‐entry, with the increased use driven mainly by insulin. No marked changes in the number of GLMs dispensed or GLM type were observed at 9‐12 months post‐entry compared with 3 months pre‐entry. Among 22 792 individuals dispensed a GLM in the 3 months prior to LTCF entry, 50.2% continued the same GLM at 9‐12 months post‐entry.ConclusionsGLM use peaked in the first 3 months following LTCF entry, driven mainly by insulin, hence, residents may benefit from close monitoring of diabetes treatment during this period.